Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedNov 04, 2025
DataAggregated Company Financials
Companies295
  • 7D2.1%
  • 3M10.6%
  • 1Y3.8%
  • YTD8.5%

In the last week, the Pharma industry is up 2.1%, with Eli Lilly up 8.5%. Meanwhile, Merck actually underperformed within the industry, shrinking 6.3% in the last week. In the last 12 months, the industry was up 3.8%. As for the next few years, earnings are expected to grow by 12% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 04 Nov 2025US$1.9tUS$396.4bUS$71.6b17.9x26.8x4.8x
Thu, 02 Oct 2025US$1.8tUS$387.9bUS$60.9b19.4x30x4.7x
Sat, 30 Aug 2025US$1.8tUS$387.9bUS$61.0b20x28.9x4.5x
Mon, 28 Jul 2025US$1.8tUS$384.0bUS$62.2b18.2x29.2x4.7x
Wed, 25 Jun 2025US$1.7tUS$382.7bUS$61.2b17.9x28.2x4.5x
Fri, 23 May 2025US$1.7tUS$382.6bUS$61.2b17.3x27x4.3x
Sun, 20 Apr 2025US$1.7tUS$380.5bUS$48.4b16.1x36.1x4.6x
Tue, 18 Mar 2025US$1.8tUS$380.5bUS$35.2b16.2x52.6x4.9x
Thu, 13 Feb 2025US$1.9tUS$380.8bUS$38.9b18x47.9x4.9x
Sat, 11 Jan 2025US$1.8tUS$369.3bUS$31.2b16.7x57.5x4.9x
Mon, 09 Dec 2024US$1.9tUS$373.8bUS$30.6b19.3x61.3x5x
Wed, 06 Nov 2024US$1.9tUS$373.5bUS$29.7b19.8x63.3x5x
Fri, 04 Oct 2024US$2.0tUS$364.1bUS$25.2b18.5x79x5.5x
Sun, 01 Sep 2024US$2.1tUS$364.1bUS$25.5b18.1x81.5x5.7x
Tue, 30 Jul 2024US$1.9tUS$357.5bUS$12.8b16.2x152.1x5.4x
Thu, 27 Jun 2024US$2.0tUS$357.6bUS$14.0b15.7x140.8x5.5x
Sat, 25 May 2024US$1.9tUS$358.3bUS$14.1b17.9x134.5x5.3x
Mon, 22 Apr 2024US$1.8tUS$357.7bUS$29.8b20.6x59.9x5x
Wed, 20 Mar 2024US$1.9tUS$355.3bUS$22.5b19.8x83.9x5.3x
Fri, 16 Feb 2024US$1.9tUS$354.9bUS$22.9b33.3x81.3x5.2x
Sun, 14 Jan 2024US$1.8tUS$375.2bUS$33.9b26.3x52.6x4.7x
Tue, 12 Dec 2023US$1.7tUS$375.1bUS$33.9b26.7x48.9x4.4x
Thu, 09 Nov 2023US$1.7tUS$375.0bUS$34.2b21.6x48.5x4.4x
Sat, 07 Oct 2023US$1.7tUS$381.8bUS$43.8b18.5x38.2x4.4x
Mon, 04 Sep 2023US$1.7tUS$381.4bUS$43.7b19.6x39.7x4.5x
Wed, 02 Aug 2023US$1.7tUS$379.1bUS$44.0b19.2x38.5x4.5x
Fri, 30 Jun 2023US$1.7tUS$392.8bUS$60.1b19.1x29x4.4x
Sun, 28 May 2023US$1.7tUS$392.9bUS$60.6b17.8x27.6x4.3x
Tue, 25 Apr 2023US$1.7tUS$402.6bUS$63.3b17.5x26.3x4.1x
Thu, 23 Mar 2023US$1.5tUS$401.1bUS$69.3b15.4x22.2x3.8x
Sat, 18 Feb 2023US$1.6tUS$401.8bUS$68.4b18.8x23.9x4.1x
Mon, 16 Jan 2023US$1.7tUS$403.7bUS$70.7b17.6x24.6x4.3x
Wed, 14 Dec 2022US$1.8tUS$403.7bUS$70.7b17x25.1x4.4x
Fri, 11 Nov 2022US$1.7tUS$403.6bUS$71.2b13x24.1x4.3x
Price to Earnings Ratio

24.1x


Total Market Cap: US$1.7tTotal Earnings: US$71.2bTotal Revenue: US$403.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 52.6x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 26.8x which is lower than its 3-year average PE of 52.6x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.91%
Healthcare-1.12%
Pharma2.14%
Pharma2.14%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$896.538.5%
+US$60.8b		11.2%PE43.6x
BMY Bristol-Myers SquibbUS$46.026.1%
+US$5.4b		-17.0%PE15.5x
TEVA Teva Pharmaceutical IndustriesUS$20.524.6%
+US$1.0b		10.1%PS1.4x
INDV IndiviorUS$31.2025.9%
+US$803.6m		239.9%PE52.6x
BLTE Belite BioUS$112.4019.8%
+US$610.0m		61.2%PB24.6x

Latest News

TERN
US$14.03
Terns Pharmaceuticals
7D
74.1%
1Y
97.6%
ZTS
US$144.35
Zoetis
7D
-2.2%
1Y
-17.6%
INDV
US$31.20
Indivior
7D
25.9%
1Y
239.9%
BLTE
US$112.40
Belite Bio
7D
19.8%
1Y
61.2%
MRK
US$82.49
Merck
7D
-6.3%
1Y
-19.0%

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 02
Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
PRGO
US$20.53
Perrigo
7D
-6.4%
1Y
-19.2%
PFE
US$24.66
Pfizer
7D
-0.4%
1Y
-11.2%
AMRX
US$11.20
Amneal Pharmaceuticals
7D
9.2%
1Y
33.1%

AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum

Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.
LLY
US$896.53
Eli Lilly
7D
8.5%
1Y
11.2%

LLY: Upcoming Drug Launches And Global Expansion Will Shape Future Outlook

Eli Lilly’s fair value estimate has increased from $891.62 to $919.33. This reflects analysts' upward price target revisions following stronger than expected quarterly results and an improved earnings outlook.
BMY
US$46.02
Bristol-Myers Squibb
7D
6.1%
1Y
-17.0%
JNJ
US$186.26
Johnson & Johnson
7D
-2.1%
1Y
17.7%
ELAN
US$22.85
Elanco Animal Health
7D
2.6%
1Y
81.9%
TLRY
US$1.31
Tilray Brands
7D
-10.9%
1Y
-24.3%

Upcoming Federal Policy Shifts Will Open New Opportunities In Cannabis Markets

Analysts have raised their price target on Tilray Brands from $1.50 to $2.00, citing recent shifts in U.S. federal policy toward cannabis and the company's strong positioning to benefit from potential market expansion. Analyst Commentary Following the price target increase, analysts have shared both optimistic and cautious perspectives on Tilray Brands, reflecting on the company's future prospects and potential risks.
CRNX
US$42.85
Crinetics Pharmaceuticals
7D
-3.4%
1Y
-24.6%
TEVA
US$20.52
Teva Pharmaceutical Industries
7D
4.6%
1Y
10.1%

Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries

Teva Pharmaceutical Industries' analyst price target has increased modestly, rising by $0.22 to approximately $24.44 per share. Analysts cite improved pricing and volume trends, along with positive expectations for key drugs and limited Q3 surprises.
RGC
US$13.56
Regencell Bioscience Holdings
7D
-17.9%
1Y
6,245.8%